saving the lives of liver disease patients

Our mission

Versantis is a preclinical stage pharmaceutical company focused on rare liver diseases. We are committed to the development of life-saving therapies for acute liver failure patients for which the current available care is not satisfactory.

A life-saving therapy

Versantis’ lead product candidate, VS-01, is the first safe and effective treatment for acute-on-chronic liver failure (ACLF), a life-threatening condition of high unmet medical need. The mortality of ACLF patients is alarming due to multi-organ failures resulting in a dangerous accumulation of toxins in the blood. The versatile mechanism of action of VS-01 can support simultaneously the affected organs (liver, kidneys, brain) and clear these toxins from the body.

discover the full potential of our pipeline...


Jul 2016
Versantis wins a Cydan scholarship!

Jun 2016
Japanese patent granted!

May 2016
VS-01 received the Orphan Drug Designation from the EMA! 

Versantis is selected for Mass Challenge 2016 Accelerator!

more news and more details...


Awards and supports




Versantis AG
c/o ETH Zurich
Otto-Stern-Weg 7, HPL D16.2
8093 Zurich


Copyright © 2016
Versantis AG